Cubicin (daptomycin, Cubist Pharmaceutical).
A novel cyclic lipopeptide antibiotic for complicated skin and skin structure infections caused by susceptible strains of these gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae sub-species equisimilis, and Enterococcus faecalis (vancomycin-susceptible strains only). The first antibiotic in this class to be approved.
* Recommended Dosage: Administered intravenously in a dosage of 4 mg/kg once every 24 hours for 7-14 days.
* Special Considerations: Creatinine phosphokinase (CPK) levels should be checked weekly, with more frequent checks for patients with unexplained elevations. Elevated CPK levels indicating muscle injury were rare in studies; most patients with elevations, which returned to normal after treatment, were asymptomatic, the Food and Drug Administration said.
* Comment: Cubicin binds to bacterial membranes, causing rapid depolarization of membrane potential; this leads to inhibition of protein, DNA, and RNA synthesis, resulting in bacterial cell death. Approval was based on studies in more than 1,400 adults showing that Cubicin was equal to standard treatments, such as vancomycin, or a semisynthetic penicillin such as oxacillin or nafcillin, in treating complicated skin and skin structure infections, the FDA said in a statement.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||New & Approved|
|Publication:||Family Practice News|
|Article Type:||Brief Article|
|Date:||Nov 15, 2003|
|Previous Article:||Inspra (eplerenone, Pfizer).|
|Next Article:||Good enough? Or good enough to increase the odds of an MI in the next ten years?|